Further studies revealed that higher PD-L1 expression in low m6A received better immunotherapy, suggesting that the lymphoid infiltrating cells in the tumor microenvironment can enhance the efficacy of immune check blocking therapy, while stromal cells can exert an anti-immune check blocker effect. This evidence concerns the gene CD274 and neoplasm.